However, while early findings are promising, more robust clinical research is needed to confirm these effects.
Take these as directed on the label rather than at maximum doses, since excessive use can create dependency
Standard clinical recommendation (12 to 24 months) The length of semaglutide treatment for weight loss can differ, but many doctors suggest staying on it for at least 12 to 24 months

Best For Patients who have plateaued on semaglutide or tirzepatide Patients with significant weight to lose (50+ pounds) Patients with fatty liver disease (MASLD/NAFLD) or metabolic syndrome Patients who want access to the most advanced mechanism currently available Patients with established GLP-1 experience and good tolerance Side Effect Comparison All three medications share a similar side effect profile driven primarily by gastrointestinal effects: Common Side Effects (All Three) Nausea most common during dose escalation, usually resolves within 2 to 4 weeks at each dose level Diarrhea reported by 15 to 25 percent of patients Vomiting reported by 8 to 15 percent Constipation reported by 6 to 12 percent Decreased appetite nearly universal and considered therapeutic Tirzepatide and retatrutide may have slightly higher rates of GI side effects than semaglutide due to the additional pathway activation

USADA and other anti-doping organizations have spent years warning athletes about the potential legal and eligibility risks of using unapproved substances whether via prescription drugs or unvetted supplements while also articulating the health risks for elite athletes and others looking to gain a small advantage in the gym
The gastrointestinal side effects common with GLP-1 receptor agonistsincluding nausea, diarrhea, constipation, and abdominal discomfortmay overlap with or potentially exacerbate symptoms related to altered bile flow after cholecystectomy